萊寶高科(002106.SZ)一季度淨利預增646.57%-770.99%
格隆匯4月13日丨萊寶高科(002106.SZ)發佈2020年第一季度業績預告,歸屬於上市公司股東的淨利潤6000萬元-7000萬元,同比增長646.57%-770.99%。
2020年第一季度,公司積極採取措施,努力克服新冠肺炎疫情帶來的不利影響,全力復工復產交付產品訂單。與去年同期相比,本報告期公司中大尺寸電容式觸摸屏全貼合產品銷量及銷售收入增長,生產效率提升,產品銷售毛利相應增加;此外,本報告期財務費用較去年同期減少約4000多萬元,主要是本報告期美元兑人民幣匯率升值產生匯兑收益,而上年同期美元兑人民幣匯率貶值產生匯兑損失影響所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.